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https://doi.org/10.1053/j.gastro.2017.10.043BACKGROUND & AIMS: Cholangiocarcinomas (CCA) are
resistant to chemotherapy, so new therapeutic agents are
needed. We performed a screen to identify small-molecule
compounds that are active against CCAs. Levels of micro-
RNA 21 (MIR21 or miRNA21) are increased in CCAs. We
investigated whether miRNA21 mediates resistance of CCA
cells and organoids to HSP90 inhibitors. METHODS: We
performed a high-throughput screen of 484 small-molecule
compounds to identify those that reduced viability of 6 hu-
man CCA cell lines. We tested the effects of HSP90 inhibitors
on cells with disruption of the MIR21 gene, cells incubated
with MIR21 inhibitors, and stable cell lines with inducible
expression of MIR21. We obtained CCA biopsies from patients,
cultured them as organoids (patient-derived organoids).
We assessed their architecture, mutation and gene
expression patterns, response to compounds in culture,
and when grown as subcutaneous xenograft tumors in mice.
RESULTS: Cells with IDH1 and PBRM1 mutations had the
highest level of sensitivity to histone deacetylase inhibitors.
HSP90 inhibitors were effective in all cell lines, irrespective
of mutations. Sensitivity of cells to HSP90 inhibitors
correlated inversely with baseline level of MIR21. Disrup-
tion of MIR21 increased cell sensitivity to HSP90 inhibitors.
CCA cells that expressed transgenic MIR21 were more
resistant to HSP90 inhibitors than cells transfected with
control vectors; inactivation of MIR21 in these cells
restored sensitivity to these agents. MIR21 was shown to
target the DnaJ heat shock protein family (Hsp40) member
B5 (DNAJB5). Transgenic expression of DNAJB5 in CCA cells
that overexpressed MIR21 re-sensitized them to HSP90 in-
hibitors. Sensitivity of patient-derived organoids to HSP90
inhibitors, in culture and when grown as xenograft
tumors in mice, depended on expression of miRNA21.
CONCLUSIONS: miRNA21 appears to mediate resistance of
CCA cells to HSP90 inhibitors by reducing levels of DNAJB5.
HSP90 inhibitors might be developed for the treatment of
CCA and miRNA21 might be a marker of sensitivity to these
agents.Keywords: Organoid; AUY922; Bile Duct Cancer; DNAJB5.
holangiocarcinomas (CCA) are tumors with dismal
1–4Cprognosis. Surgery is the only curative treatment
modality in CCA; however, less than 30% of patients are
diagnosed with resectable disease.5,6 In advanced CCA, the
efﬁcacy of systemic treatment is limited by drug resis-
tance.5 A combination treatment with cisplatin and gem-
citabine is recommended as ﬁrst-line standard for patients
with inoperable CCAs, based on data from the ABC-02 tri-
al.7–9 However, long-term outcome is still poor,5 high-
lighting the need for the identiﬁcation of novel therapeutics
along with appropriate strategies for clinical
implementation.
Attempts to test the efﬁcacy of targeted therapies and
small molecules against CCAs have been made without a
proper phase of target selection and validation, leading to
repeated failures in small and unselected populations of
CCA patients.10–13 Notably, a phase III trial failed to show a
beneﬁt from the addition of erlotinib to a gemcitabine-
platinum combination in metastatic CCAs that were not
enriched for the appropriate molecular subtype.14
Molecularly targeted small-molecule drugs are low-
molecular-weight compounds that regulate biological
EDITOR’S NOTES
BACKGROUND AND CONTEXT
Cholangiocarcinoma is a deadly disease which is often
diagnosed at an advanced stage where treatment
options are limited. Novel therapies are urgently needed
to improve the survival of cholangiocarcinoma patients.
NEW FINDINGS
HSP90 inhibitors may be promising in the treatment of
cholangiocarcinoma that do not express high levels of
microRNA21. Mini-tumors can be grown in the lab
starting from the biopsy of metastatic
cholangiocarcinoma and can be used as a novel
disease model for the study of cancer biology and drug
sensitivity.
LIMITATIONS
Needs clinical validation in patients.
IMPACT
microRNAs and organoids should be included in drug
discovery programmes that can identify novel
therapeutic strategies for cholangiocarcinoma patients.
March 2018 MIR21 as Biomarker of Resistance to HSP90 Inhibition 1067processes and can rapidly diffuse across cell membranes so
that they can reach intracellular sites of action.15 Small
molecules have entered clinical practice for the treatment of
other forms of solid malignancies, where the dependence of
the cancer on speciﬁc pathways is understood. Here, we
report data from a high-throughput screen (HTS) of a library
of small-molecule drugs and chemical tools in human CCA
cell lines that have been genetically characterized for the
most frequent mutations observed in human CCA, along
with validation in ex vivo and in vivo models of promising
compounds and relative biomarkers of response. Our
approach has enabled us to identify molecularly targeted
small molecules that have activity against CCAs and related
biomarkers that may inform future clinical trial design.BA
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HTS
A custom compound library including 484 small mole-
cules was developed in the Cancer Research UK Cancer
Therapeutics Unit at the Institute of Cancer Research
(Supplementary Table 1). Cells were plated into a poly-
propylene 384-well assay plate (Greiner Bio-One, Frick-
enhausen, Germany) for 48 hours before compounds were
screened at the ﬁnal concentration of 80 nmol/L, 200 nmol/
L, and 800 nmol/L in 0.3% (v/v) dimethyl sulfoxide (DMSO)
by dispensing 125 nL compound solution from a source plate
containing the compounds at a concentration of 32 mmol/L, 80
mmol/L, and 320 mmol/L in 2% (v/v) DMSO, into the central
320 wells of a 384-plate. 0.3% (v/v). DMSO was used as a
vehicle control. Cell viability was assessed after 72 hours by
ﬂuorimetric assay (CellTiter-Blue; Promega Madison, WI). The
cell viability measurement from each hit was normalized to
those of cells exposed to vehicle only. Each cell line was tested
in triplicate. Statistical signiﬁcance (P < .05) was determined
by 2-sided t-test across 3 replicates.Statistical Analyses
Statistical analyses were performed by GraphPad Prism 6
(La Jolla, CA). Results are expressed as mean ± SD, unless
indicated otherwise. Groups that were normally distributed
were compared with either a 2-tailed Student’s t test
(for analysis of 2 groups) or using 2-way ANOVA to compare
multiple groups. Non-parametric data were analyzed using a
Wilcoxon–Mann-Whitney U test when comparing 2 groups.
Signiﬁcance was accepted when P was <.05.Patient-derived Organoids (PDO)
One core biopsy was obtained from a patient with advanced
intrahepatic CCA (iCCA) after ethical approval within the
CCR3689 protocol at the Royal Marsden Hospital (London and
Surrey, UK). For the colorectal cancer PDOs, 1 core biopsy was
obtained from a liver metastasis of a chemo-refractory colo-
rectal cancer patient (protocol CCR4164). The biopsy was
minced, conditioned in phosphate-buffered saline/EDTA
5 mmol/L for 15 minutes at room temperature, and digested in
phosphate-buffered saline/EDTA containing 2x TrypLe
(Thermo Fisher Scientiﬁc, Waltham, MA) for 1 hour at 37C.
Following digestion, mechanical force was applied to facilitate
cell release in solution. Dissociated cells were collected in
Advanced Dulbecco’s modiﬁed Eagle medium/F12 (Thermo
Fisher Scientiﬁc), suspended in growth factor reduced matrigel
(Corning Inc, Corning, NY), and seeded. The matrigel was then
solidiﬁed and overlaid with 500 mL of complete human orga-
noid medium, which was subsequently refreshed every 2 days.
PDOs were cultured in Advanced Dulbecco’s modiﬁed Eagle
medium/F12, supplemented with 1x B27 additive and 1x N2
additive (Thermo Fisher Scientiﬁc), 0.01% bovine serum
albumin, 2 mmol/L L-glutamine, 100 units/mL penicillin-
streptomycin, and containing the following additives:
epidermal growth factor, noggin, R-spondin 1, gastrin,
ﬁbroblast growth factor-10, ﬁbroblast growth factor F-basic,
Wnt-3A, prostaglandin E2, Y-27632, nicotinamide, A83-01,
SB202190, and hepatocytes growth factor (Pepro-Tech, London,
UK). Passaging of PDOs was performed using TrypLe. PDOs were
biobanked in fetal bovine serum (Thermo Fisher Scientiﬁc)
containing 10% DMSO (Sigma-Aldrich, St. Louis, MO).PDO Histology
PDOs were harvested out of matrigel by inoculating them
with 1 mL Cell Recovery Solution (Corning Inc) for 60 minutes
at 4C. Organoids were then collected in cold phosphate-
buffered saline, pelleted, and ﬁxed in formalin 10% (Sigma-
Aldrich) for 60 minutes. Following ﬁxation, organoids were
washed and resuspended in 200 mL of warm agarose 2%. The
agarose pellet was dehydrated using ethanol and embedded in
parafﬁn using a standard histologic protocol.
PDO NanoString Analysis
One hundred ng of total RNA extracted from PDOs and
matching formalin-ﬁxed parafﬁn-embedded (FFPE) biopsies
were run with the nCounter PanCancer Progression panel
(Nanostring Technologies, Seattle, WA) according to the
manufacturer’s instructions. Raw data were normalized using
the NanoStringNorm R package version 1.1.21 following
recommended parameters and median centered by genes.
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DNA and RNA were extracted using the Qiagen AllPrep
DNA/RNA/microRNA (miRNA) Universal kit (Qiagen, Hilden,
Germany). Targeted library preparation and DNA sequencing
were outsourced to GATC Biotech (Constance, Germany). In
brief, DNA libraries were prepared with the ClearSeq Compre-
hensive Cancer panel (Agilent Technologies, Santa Clara, CA) that
targets 151 cancer-related genes, using SureSelectV6 chemistry
(Agilent Technologies). Paired-end sequencing (2 x 125 bp) was
then performed using Illumina technology.
3D Organoid Compound Assay and Screening
Organoids (30 mL of growth factor reduced matrigel
containing 6000 cells) were seeded in 96-well cell culture
plates; after matrigel solidiﬁed it was overlaid with 70 mL of
complete human organoid medium. Complete medium was
refreshed once after 24 hours. Compound was added 3 days
later and compound-containing medium was further refreshed
every 2 days. After 11 days medium was removed and replaced
with 100 mL of complete human organoid medium containing
10% CellTiter-Blue Cell Viability Assay (Promega). The orga-
noid compound screen was conducted in 96-well cell culture
plates using a custom-made library of 55 compounds and 5
DMSO controls; it was conducted in triplicate, using a concen-
tration of 1 mmol/L for all compounds.
PDO-derived Xenografts
All in vivo experiments were performed in accordance with
the local ethical review panel, the UK Home Ofﬁce Animals
(Scientiﬁc Procedures) Act 1986, the United Kingdom National
Cancer Research Institute guidelines for the welfare of animals
in cancer research,13 and the ARRIVE guidelines. Further
details about animal experiments and additional methods can
be found in the Supplementary information. Animals were
housed in speciﬁc pathogen-free rooms in autoclaved, aseptic
micro isolator cages with a maximum of 5 animals per cage.
Food and water were provided ad libitum. One hundred mL of
matrigel containing approximately 20,000 small MIR21 TRIPZ
organoids were injected subcutaneously in the ﬂank of 6- to
7-week-old NOD scid gamma animals (Charles River Labora-
tories, Wilmington, MA) while they were kept on doxycycline
diet (LabDiet 5053 w/1250 ppm doxycycline blue; LabDiet,
St. Louis, MO). About 10 weeks post inoculation, tumors were
passaged and equal fragments of tumors were implanted sub-
cutaneously into a next generation of mice to obtain a total of
18 mice. Eight mice were treated with vehicle, while 10 mice
were treated with AUY922 (25 mg/kg intraperitoneally) 3=
Figure 1. HTS using a library of small-molecule compounds in C
lines. (B) HTS was performed using a custom library of 484 com
measured by CellTiter-Blue assay and normalized to that of DM
licates in 6 CCA cell lines. Compounds that signiﬁcantly inhibited
3 concentrations in each cell line were considered for the graph
Data from the HTS relative to the activity of gemcitabine (GEM)
and SD of 3 independent replicates. P <.05 for all cell lines. (D
same class (ie, HSP90 inhibitors). Compounds that were signiﬁ
centrations in each cell line were represented in the radar plot w
class in the selected cell line. Enrichment of selected classes o
deacetylase inhibitors in SNU-1079 cells (all 4 compounds i
microtubule-targeted compounds and mTOR inhibitors are shotimes a week. After 2 weeks, mice were randomized to stay
on doxycycline diet or to move onto a doxycycline-free diet
for an additional 2 weeks while treatment was continued.
Tumor volume was determined using the following
formula: ¼4.19*(diam1 / 4 þ diam2 / 4)
ˇ
3. After 4 weeks of
treatment, mice were culled and their tumors were excised,
ﬁxed in formalin, and embedded in parafﬁn.Results
HTS With a Small-molecule Compound Library
Identiﬁed Vulnerabilities that can be Exploited
for Novel Therapeutics in CCA
To explore the activity of small molecules in CCA,
we screened a library of 484 molecularly targeted
small-molecule compounds (Supplementary Table 1) for
their effect on the viability of human CCA cell lines. Both
iCCA and extrahepatic CCA cell lines were included.
Next-generation sequencing revealed that these cell lines
were representative of human CCA tissues. We used a
64-gene panel that included the most frequently mutated
genes in human CCA16 and found that mutations that are
present in >10% in human tissues were represented in our
cell lines, with the exceptions of ARID1 (Figure 1A,
Supplementary Table 2). EGI-1, TFK-1, SNU-1196, SW1, CCLP,
and SNU-1079 cell lines were selected for the screening in
view of their origin and their growth rate and pattern.
Compounds were screened at 3 different concentrations
(80 nmol/L, 200 nmol/L, and 800 nmol/L) in triplicate for
each cell line. A number of compounds (median ¼ 68 per
cell line) had a signiﬁcant effect on cell viability at all con-
centrations tested (Supplementary Table 3, Figure 1B).
Gemcitabine, a well-known active drug in CCA, had signiﬁ-
cant activity at all concentrations tested, in each cell line,
conﬁrming the validity of our approach (Figure 1C). To
assess which pathway may be more relevant as a potential
target of therapy in CCA, we grouped compounds with
different chemical structure that acted on the same molec-
ular target and investigated if there was an enrichment in
selected molecular pathways amongst the drugs that were
signiﬁcantly active across the cell lines (Figure 1D).17,18 We
observed enrichment for microtubule-associated com-
pounds and mTOR inhibitors in all cell lines. Clinical trials
are ongoing for microtubule-targeted compounds such as
Nab-Paclitaxel and mTOR inhibitors such as Everolimus.
Interestingly, there was an enrichment of histone-deacetylaseCA cell lines. (A) The origin and mutational status of CCA cell
pounds. DMSO was used as vehicle control. Cell viability was
SO. HTS was run at 3 concentrations in 3 independent rep-
cell proliferation compared with vehicle control (P <.05) at all
and number of compounds active per cell line is reported. (C)
in each cell line compared with DMSO. Bars represent mean
) Compounds acting on the same target were included in the
cantly active in comparison to DMSO (P <.05) at all 3 con-
ith the radar value representing the number of compounds per
f compounds was identiﬁed, such as in the case of histone-
ncluded in the library). In the callout, square data without
wn.
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harbors mutations in the isocitrate dehydrogenase 1 (IDH1)
and polybromo1 (PBRM1) chromatin remodeling genes.
In line with previous data,19 SNU-1079 cells also showed
hypersensitivity to dasatinib (Supplementary Table 3). A
number of EGFR inhibitors had a signiﬁcant effect on the
viability of SW1, SNU-1196, and TFK cell lines. Interestingly,
both aurora kinase and heat shock protein (HSP)90 inhibitors
were effective in all cell lines.Association Between Mutational Status
of CCA Cell Lines and Their Sensitivity to
Selected Compounds
To investigate whether selected mutations were associ-
ated with sensitivity to speciﬁc targeted agents, we ran an
analysis for BRCA-associated protein (BAP1) and TP53
mutations because these were present in more than 1 cell
line (Supplementary Figure 1A,B). Our analysis revealed
that BAP1-mutant (MUT) CCA cell lines were more sensitive
(P < .05) to a range of small molecules that include com-
pounds with activity on PI3K pathway: SANT-2 (SMO
antagonist), ABT-737 (inhibitor of Bcl-(X)L, Bcl-2, and
Bcl-W), LY294002 (PI3Ka/b/d inhibitor), PIK-93 (PI3Ka/g
inhibitor), SB203580 (p38 MAPK inhibitor), and SB590885
(BRAF inhibitor). TP53-MUT cells did not show any
increased sensitivity to the compounds we screened in
comparison to WT cells. However, we noticed a signiﬁcant
(P < .05) correlation between mutations in TP53 and
resistance to PF-573228 (ATP-competitive inhibitor of FAK),
ABT-263 (navitoclax, a potent inhibitor of Bcl-(X)L, Bcl-2,
and Bcl-W), and MM-102 (MLLT1 inhibitor). The limited
number of cell lines does not enable to draw deﬁnitive
conclusions, even though these ﬁndings suggest potential
associations that may deserve further investigation.ND L
BI
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YFGFR-targeting Compounds in CCA Cell Lines
Given emerging data on the activation of the ﬁbroblast
growth factor receptor (FGFR) pathway in CCA,20–23 we
looked at the effect on cell viability of the 6 compounds in
our screen that act on FGFR. The effect of these com-
pounds on cell viability was most consistent at the highest
concentration tested, 800 nmol/L (Figure 2A). Whilst=
Figure 2.MIR21 expression is associated with sensitivity to H
compounds with different degrees of activity on FGFR and HSP
compound compared with DMSO are shown. Gemcitabine is r
plates for 48 hours and AUY922 added at scalar concentratio
was measured by CellTiter-Blue and GI50 generated through Pr
was generated by treating cells with scalar concentrations of
(D) Cells were subjected to reverse transfection and plated in 96-
viability was assessed by CellTiter-Blue. Positive control cell d
infected with MIR21 or CTRL TRIPZ viral vector to generate stab
and normalized to that of RNU48. Bars represent mean and SD
96-well plates and treated with DMSO or AUY922 (10 nmol/L). A
expression (indicated by grey area). Cell viability was measu
plotted against Y axis (DMSO-treated cells toward left Y axis, w
SD of 12 replicates. Statistical analysis is reported in Supplem
points are shown.brivanib (VEGFR/FGFR inhibitor) and the multi-kinase
inhibitor pazopanib had no effect, both danusertib (a
pan-aurora kinase inhibitor with an off-target effect on
FGFR1) and ponatinib (a Src and Bcr-Abl kinase inhibitor
with activity on all 4 FGFRs)24 reduced CCA cell viability.
However, we acknowledge that our system may not be
ideal for the assessment of angiogenesis/stroma-directed
drugs and that our cells are not known to carry FGFR2
alterations.
HSP90 Inhibitors are Effective in CCA Cell Lines
We have previously observed enrichment in aurora
kinase and HSP90 inhibitors amongst the signiﬁcant hits
from our CCA HTS. While aurora kinase inhibitors appear to
be quite toxic in solid tumours,25 a recent report showed
that HSP90 inhibition is effective and tolerable in in vivo
CCA preclinical models.26 HSP90 inhibition is attractive in
CCA because HSP90 interacts with and controls a variety of
client proteins that play a key role in CCA pathogenesis,
such as EGFR, PTEN, PI3K, HER2, HER3, and PRKA. More-
over, recent evidence suggests that HSP90 inhibition is
remarkably effective in tumors with FGFR fusions and
activation of the IL6/STAT pathway.27,28
Our small-molecule compound library included 9 HSP90
inhibitors, including those from different chemical series,
and 78% were active across our CCA cell line panel, with the
highest activity recorded for AUY922, 17-AAG, 17-DMAG,
ganetespib, and BIIB021 (Figure 2A). Notably, the growth
inhibitory (GI)50 of AUY922, a potent HSP90 inhibitor,
29 was
in the nanomolar range in all of the CCA cell lines tested
(Figure 2B). We found no correlation between the most
frequent mutations in CCA and the activity of the HSP90
inhibitors in our CCA cell lines.
MIR21 as Driver of Resistance to
HSP90 Inhibitors
Previously, miRNAs have been shown to modulate
drug sensitivity and to act as biomarkers of drug
response.1,4,30–37 MIR21 is an oncogenic miRNA that drives
CCA pathogenesis and sensitization to conventional
chemotherapy drugs.38,39 Thus, we investigated if MIR21
could be used as a biomarker of response to HSP90 inhi-
bition in CCA. Interestingly, we noticed that MIR21SP90 inhibitors. (A) Our compound library included 6 and 9
90. Changes in cell viability (Log scale) induced by the given
eported as positive control. (B) Cells were plated in 384-well
ns for 72 hours. DMSO was used as control. Cell viability
ism software. (C) MIR21 was assessed in CCA cell lines. GI50
AUY922 for 72 hours. Data represent mean of 3 replicates.
well plates. After 48 hours, AUY922 50nmol/L was added. Cell
eath was used as transfection control. (E) CCLP cells were
le clones. miR21 expression was assessed by Taqman assays
of 3 replicates. (F) Doxycycline-induced cells were plated in
fter 72 hours, doxycycline was removed to deactivate MIR21
red at selected time points by a Celigo S cytometer and
hile AUY922-treated cells toward right Y axis). Bars represent
entary Table 4. (G) Representative pictures at different time
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Figure 3. DNAJB5 is a target of MIR21. (A) MIR21 and CTRL TRIPZ viral vector CCLP cells were treated with AUY922 for 72
hours and proteins collected for the HSP array. Dots in the yellow boxes represent DNAJB5 protein expression in duplicate.
Full details of the antibody plate map are provided below the blots. Quantiﬁcation of protein expression normalized on the
averaged positive controls is shown in the right panel. Bars represent LOG10 of mean and standard deviation of 2 replicates.
Linear fold change of MIR21 vector relative to CTRL vector is 0.89 for HSP60, 0.88 for HSP70, and 0.52 for HSP40.
(B) Schematic representation of the MIR21 binding site within the 3’UTR of DNAJB5 mRNA (RNAHybrid). (C) MIR21 and CTRL
TRIPZ-infected CCLP cells were treated with DMSO and AU922 for 72 hours. HSP70 was used a marker of target engagement
for AUY922 activity. (D) Cells were plated in 6-well dishes and transfected with a pMirTarget vector containing DNAJB5-3’UTR.
Luciferase activity was read after 24 and 48 hours and normalized to renilla activity for each transfected well. Bars represent
mean and SD of 3 replicates. (E) Cells were transfected with a plasmid over-expressing DNAJB5 or an empty plasmid pCMV6
for 24 hours, and then treated with AUY922. Cell viability was measured 48 hours later using CellTiter-Blue. Bars represent
mean and SD of 6 replicates.
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as cell lines with high levels of MIR21 expression had higher
GI50 values for AUY922 (Figure 2C). Sensitivity to AUY922
was signiﬁcantly increased in CCA cells transfected with a
locked nucleic acid MIR21 inhibitor compared with those
transfected with a negative control locked nucleic acid
inhibitor (Figure 2D). To validate the relationship between
MIR21 expression and AUY922 sensitivity, we conducted a
high-throughput compound screen in RKO cells that had
been engineered to knock out the MIR21 locus (MIR21KO)
and parental isogenic wild type (WT) cells.40 A number of
HSP90 inhibitors produced a larger reduction in cell
viability in MIR21KO cells in comparison with WT cells
(Supplementary Figure 2A), with AUY922, 17-AAG, 17-
DMAG, and ganetespib showing the highest activity. Whentreated with HSP90 inhibitors, MIR21KO RKO cells were
more sensitive than WT RKO cells (Supplementary
Figure 2B). Correspondingly, the GI50 for AUY922 was
found to be 35 nmol/L in WT cells and 17 nmol/L in
MIR21KO cells (Supplementary Figure 2C). Interestingly, we
could detect no difference in the sensitivity to AUY922 in
WT and MIR21KO DLD1 cells, which is consistent with the
lower baseline level of MIR21 in DLD-1 cells and their likely
lower dependence on MIR21 (Supplementary Figure 2D).
Indeed, DLD-1 WT cells were more sensitive to AUY922
than RKO WT, while silencing of MIR21 in RKO cells
restored their sensitivity (Supplementary Figure 2E,F).
To validate the role of MIR21 in driving resistance to
HSP90 inhibition, we infected MIR21KO DLD-1 cells with an
inducible MIR21 or control (CTRL) viral vector
Figure 4. PDOs were
derived from a patient with
metastatic chemo-
refractory iCCA. (A) Trend
in serum Ca19.9 is repre-
sented over time.
Biochemical and radiolog-
ical partial response was
observed to chemotherapy
with cisplatin and gemci-
tabine, while progressive
disease was recorded after
carboplatin-gemcitabine
or Folfox chemotherapy.
Computed tomography
(top panel) and positron-
emission tomography
(bottom panel) images are
shown for indicated time
points. (B) H&E (left) and
immunohistochemistry for
Cytokeratines 7 and 19
(right) of the FFPE
research biopsy. Scale
bars in mm.
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AUY922. Enforced expression of MIR21 signiﬁcantly
increased resistance to AUY922 (P < .05), when compared
with the effect of infection with an empty CTRL vector
(Supplementary Figure 3A and Supplementary Video 1).
Indeed, in co-culture with non-infected MIR21KO DLD-1
cells, MIR21-induced DLD-1 cells could proliferate in the
presence of AUY922 (Supplementary Figure 3B and
Supplementary Video 2). To ascertain if these results could
be extended to CCA, we generated Tet-on inducible clones
for the over-expression of MIR21 in the CCLP cell line
(Figure 2E). In line with previous data, CCLP cells with
enforced expression of MIR21 were signiﬁcantly more
resistant to AUY922 than cells transfected with the CTRLvector. Accordingly, deactivation of the Tet-on system
restored sensitivity to AUY922 in CCLP cells (Figure 2F,G,
Supplementary Table 4). Comparable data were also
obtained in the EGI CCA cell line (Supplementary Figure 4).DNAJB5 is a Mediator of MIR21-dependent
Resistance to AUY922
To gain insight into the relationship between MIR21 and
the HSPs, we measured the expression levels of a panel of
HSPs and co-chaperones in Tet-on MIR21 vector CCLP cells
treated with AUY922. A multiplex sandwich immunoassay
showed a reduction in the level of HSP40 (encoded by DnaJ
heat shock protein family (Hsp40) member B5, DNAJB5) in
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YMIR21 vector cells compared with CTRL cells (Figure 3A). In
silico analysis of the DNAJB5 sequence revealed a binding
site for MIR21 within its 3’UTR (Figure 3B). Western blot
analysis conﬁrmed induction of DNAJB5 upon AUY922
treatment and reduction in DNAJB5 expression in MIR21
over-expressing cells (Figure 3C), and a luciferase reporter
assay conﬁrmed a direct interaction between MIR21 and the
3’UTR of DNAJB5 (Figure 3D). Interestingly, enforced
expression of DNAJB5 in MIR21 over-expressing cells
re-sensitized CCLP cells to AUY922 (Figure 3E), conﬁrming
that DNAJB5 may be a mediator of MIR21-induced resistance.
Correlation Between MIR21 Expression
and Sensitivity to AUY922 in PDOs
and PDO-derived Tumor Xenografts
PDOs have recently emerged as organotypic cultures
that recapitulate the complex 3-dimensional organization
of cancer better than 2D tumor cell lines.41–43 To assess
the clinical relevance of our ﬁndings, we tested AUY922
activity in PDOs established from the liver biopsy of a
chemoresistant iCCA patient (Figure 4, Figure 5A). PDOs
retained the same morphology of the primary tumor
(Figure 5B), as well the same positivity for cytokeratin
7 and 19 (Figure 5C, Figure 4B). Gene expression proﬁling
showed that the transcriptome of PDOs recapitulated that of
the parental tissue (with a Spearman r score of 0.91 for the
housekeeping genes, and 0.61 for the whole transcriptome
[P < .0001]) (Figure 5D). DNA sequencing conﬁrmed that
the genetic background of the PDOs matched that of the
parental biopsy, with a Spearman r score of 0.96 for SNVs
(Figure 5E). CCA PDOs were tested against a panel of small-
molecule compounds and conﬁrmed resistance to ﬂuoro-
uracil and oxaliplatin that patient had received before the
development of PDO (Figure 5F). CCA PDOs were sensitive
to AUY922 (Figure 5F,G), and this sensitivity was signiﬁ-
cantly enhanced after inducible inhibition of MIR21
(Figure 5H,I). In parallel, PDOs derived from a colorectal
cancer patient with low endogenous expression of MIR21
were characterized (personal data) and tested against
AUY922 before and after MIR21 expression, conﬁrming
the relationship between miRNA expression and sensitivity
to HSP90 inhibition (Supplementary Figure 5). Next, we
generated CCA PDO-derived tumor xenografts by inocu-
lating Tet-on MIR21 PDOs in the ﬂank of NOD scid gamma
mice. Mice were treated with AUY922 or vehicle while
changes in their diet were applied to modulate the expres-
sion of MIR21. After 2 weeks of treatment mice were=
Figure 5. Sensitivity of CCA PDOs to HSP90 inhibition with a
PDOs derived from 1 biopsy core of an iCCA. Bars indicate 100
another core was used to establish PDOs. PDOs were embedd
staining for CK7 and CK19 in PDOs. Bar score in mm. (D) Total
PDOs, and subjected to NanoString analysis. Correlation of gen
gene expression (bottom). (E) DNA was extracted from the FFP
sequencing. Correlation between variant reads frequency is sho
with a number of compounds (1 mmol/L) in triplicate. Cell viab
replicates are shown relative to DMSO with DMSO set at 1. (G) C
in triplicate. (H) CCA PDOs were infected with a MIR21-inhibito
cells. Scale bars indicate 100 mm. (I) TRIPZ infected CCA PDOrandomized to stay on doxycycline diet (DOX-ON) or
changed to a doxycycline-free (DOX-OFF) diet. While a non-
signiﬁcant change was observed for vehicle-treated mice,
AUY922-treated mice on DOX-OFF diet achieved a signiﬁ-
cantly better tumor response than animals that remained
on a doxycycline diet (Figure 6A–C, Supplementary Table 5).
MIR21 expression was conﬁrmed to be inactivated in the
tumor after withdrawal of doxycycline diet, while an increase
in DNAJB5 protein expression was detected (Figure 6D).
Discussion
The best way to treat advanced CCA is still a matter of
debate within the clinical and scientiﬁc community.5,6
The ABC-02 trial has proven the efﬁcacy of platinum-
gemcitabine combination chemotherapy in the ﬁrst-line
setting.7 However, a series of clinical trials have failed to
demonstrate any beneﬁt from targeted therapies in
CCA.11,12,14,44 Despite advances having been made in the
genetic and molecular characterization of biliary tract
cancers, none of the clinical trials were designed with an
appropriate strategy of patient selection based on pre-
clinical evidence. In this study, we explored the activity of
a plethora of small-molecule compounds and probes that
have shown activity in other cancers. In this way, we hoped
to identify drug candidates and appropriate biomarkers for
use in, and to aid patient selection for, future clinical trials.
We propose that the decision to use targeted therapies
should be based on the molecular characterization of a
tumor, rather than its site of origin. Hence, in this study we
included cell lines originating from all types of CCA.
As expected, we did observe signiﬁcant activity for
gemcitabine and compounds that impair microtubule
dynamics and cause cell cycle arrest. We also found that
compounds that inhibit mTOR signaling had activity in CCA
cell lines, consistent with previous evidence suggesting
that the mTOR pathway is involved in CCA tumorigenesis
and that sirolimus may induce partial remissions in
CCA patients.45,46 Nonetheless, we did not focus on these
compounds given that clinical trials are ongoing and may
provide additional insights. The observation that histone-
deacetylase inhibitors were enriched amongst the hits in
SNU-1079 cells was in line with previous observations on
the effect of IDH mutations on the impairment of histone
demethylation.47
We and colleagues at The Institute of Cancer Research
have an interest in the therapeutic applications of HSP90
inhibitors and biomarkers of sensitivity to these agents, andnd without MIR21 modulation. (A) Phase-contrast images of
mmol/L. (B) One biopsy core was embedded in parafﬁn, while
ed into parafﬁn and stained for H&E. Bar score in mm. (C) IHC
RNA was extracted from the FFPE biopsy and the matching
e expression is shown for housekeeping genes (top) and total
E biopsy and the matching PDOs and subjected to targeting
wn. (F). CCA PDOs were plated in 96-well plates and treated
ility was tested after 11 days with CellTiter-Blue. Mean of 3
CA PDOs were treated with scalar concentrations of AUY922
r or control TRIPZ viral vector. RFPþ cells indicate infected
s were treated with scalar concentrations of AUY922.
T
Figure 6.MIR21 modulation drives sensitivity to AUY922 in CCA PDO-derived animal model. (A) Schematic representation of
in vivo studies. Vertical arrows indicate administration of DMSO or AUY922 25 mg/Kg. (B) Tumor growth curves across
different groups. Data represent mean and standard error (n ¼ 5 for AUY922 treated, n ¼ 4 for DMSO treated). P values are
shown in Supplementary Table 5. Grey area represents the period with different diets. (C) HSP70 staining was performed as
evidence of target engagement after AUY922 exposure. As expected, there was an increase in HSP70 expression after
AUY922 treatment but this was not different between the 2 randomized groups, excluding differences in animal dosing. Scale
bars: 100 mm. (D) Withdrawal of doxycycline diet from mice was associated with a signiﬁcant inactivation of MIR21 expression
and over-expression of DNAJB5. Representative pictures of in situ hybridization for MIR21 and IHC for DNAJB5 are shown.
Scale bars: 100 mm. On the right quantiﬁcation is represented. Bars indicate median with interquartile ranges.
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inhibitor AUY922.48 Shirota et al26 have recently shown that
HSP90 inhibitors have potent in vitro and in vivo anti-
proliferative activity in CCA, prompting us to investigatepotential biomarkers of sensitivity to HSP90 inhibition in
our study. HSP90 inhibitors, including AUY922, have shown
an acceptable toxicity proﬁle in humans in phase I clinical
trials,49–51 and are currently investigated in phase II clinical
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Ytrials for lung and breast cancers. To date, no reports are
available on the role of AUY922 in biliary tract cancer
patients. More interestingly, growing evidence points to a
role of HSP90 inhibitors in facilitating the anti-tumor
activity of immune cells.52,53 We showed that CCAs are
characterized by an immuno-deregulation that creates an
immunosuppressive milieu54; thus, HSP90 may be used to
reactivate an anti-tumor response in CCA. HSP90 is a key
component in a multi-chaperone complex involved in
the post-translational folding of a number of client
proteins, including microRNA-regulated proteins such as
argonaute2 (AGO2).55–57 We reasoned microRNAs may be
good biomarker candidates given their capacity to act
on several HSP90-associated proteins that drive tumori-
genesis and drug resistance. MIR21 was previously
shown to modulate cytotoxic drug response58 and is pre-
dicted to target genes that act as client proteins for
HSP90.2,3,20,21,38,59 However, microRNAs were not studied
as mediators of the response to HSP90 inhibitors to our
knowledge.60 We observed that MIR21 can drive tumor cell
proliferation in the presence of HSP90 inhibitors. Our data
suggest that it would be useful to carry out further studies
of the biomarker potential of MIR21 as a guide treatment
with HSP90 inhibitors, as well as to pursue the combination
of HSP90 inhibitors with MIR21 inhibitors in CCA. More-
over, our data suggest a generalized mechanism of resis-
tance to HSP90 inhibition and may be applied to second-
generation HSP90 inhibitors that may be clinically more
attractive.61,62 HSP70 is a well-known compensatory
mechanism of HSP90 inhibition. The stress-inducible HSP70
is central in promoting protein folding. As elegantly
described by Hartl et al,63 HSP70 is responsible for the
initial folding of substrates and their loading into HSP90. Its
afﬁnity for unfolded substrates is tightly regulated by
HSP40. Indeed, HSP40 not only delivers unfolded substrates
to ATP-bound HSP70, but it also accelerates the hydrolysis
of ATP, inducing a tighter binding of the substrate by HSP70.
We speculate that MIR21 can interfere with this balance and
thus, with the HSP90-mediated activation of client proteins,
by modulating the expression of HSP40.
We have shown here that MIR21 drives resistance both
in CCA and in non-CCA carcinoma cells. Thus, it is likely
that these ﬁndings may be extended to a number of
malignancies. Despite a general over-expression of MIR21
in cancer tissues, it is known that MIR21 is remarkably
over-expressed in a proportion of cancer patients and may
therefore serve as a valuable biomarker.39 In addition,
there is evidence that levels of circulating MIR21 can
deﬁne the prognosis of cancer patients and may act as
surrogate for miRNA expression in the tumour.34 Thus,
circulating MIR21 may represent an easily accessible tool
for the identiﬁcation of patients likely to beneﬁt from
treatment with HSP90 inhibitors.
Finally, we have provided initial evidence of the
feasibility of developing human PDOs from CCA patients.
To date, successful 3D organoids have been established
from a variety of cancer types, but no evidence has been
reported for biliary tract cancers. In these studies we show
that PDOs could be derived from 1 biopsy core, indicatingthat this technology may be attractive for clinical imple-
mentation. Our studies indicate the possibility that PDOs
may resemble the original tumor and may potentially be
used for in vitro application and manipulation within 6–8
weeks from establishment. Thus, PDOs may represent a
promising novel tool to guide treatment selection within
the life expectancy of CCA patients, and may offer an
additional platform that better recapitulates human
cancers to investigate their biology.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/
j.gastro.2017.10.043.References
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Supplementary Figure 1. (A&B) Hierarchical clustering based on the sensitivity (green) or resistance (red) of cells to
small-molecule inhibitors. Cells were considered sensitive if a compound reduced cell viability >20%, compared to DMSO,
across 3 replicates. A Chi2 test was used to identify signiﬁcant correlations between mutations and drug sensitivity. Mutated
cells clustered together, independently of tumour origin [eCCA (light blue) vs iCCA (black)]. Of note, a concentration-response
effect was observed [80nM (yellow), 200nM (orange), 800nM (red)].
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Supplementary Figure 2. (A&B) Data from the compound screening in RKO cells are shown as a colour map or a bar graph
(200nmol/L). Bars represent mean and standard deviation of three replicates. (C&D) Cells were plated in 96-well plates for
24 hours and AUY922 added at scalar concentrations for 72 hrs. DMSO was used as control. Cell viability was measured by
CellTiter-Blue and GI50 generated through Prism software. Bars represent mean and SD of 6 replicates. (E) Cell were treated
with the same concentration of AUY922 (10nmol/L) for 72 hours and cell viability assessed by CellTiter-Blue. Bars represent
mean and SD of 6 replicates. (F) miR21 expression was assessed by Taqman assays and normalized to that of RNU48. Bars
represent mean and SD of three replicates. Baseline miR-21 expression is higher in RKO compared to DLD-1 WT cells.
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Supplementary Figure 3. (A) miR-21KO DLD-1 cells were stably infected with a Tet-on TRIPZ vector enabling over-expression
of miR-21 and RFP, or a control (CTRL) empty vector expressing RFP. Cells were exposed to doxycycline to induce miR-21/
CTRL and RFP expression that were under the same promoter. RFPþ (red) cells represented induced infected cells. Induced
cells were plated in 96-well plates and AUY922 added 22 hrs later. Cell viability and RFP conﬂuency were monitored and
measured at intervals by the Incucyte Zoom. Data represent mean and SD of 12 replicates. Difference between the two curves
was statistically signiﬁcant (P< .05). Representative images are shown for selected time points. (B) miR-21KO DLD1 cells were
co-cultured with Tet-on miR-21KO miR-21 vector DLD-1 cells. Cells were induced, plated in 96-well plate, exposed to
doxycycline, and treated with AUY922 (10nmol/L). RFPþ cells represented cells that over-expressed miR-21, while RFP-
(bright-ﬁeld) cells represented miR-21KO cells. Phase contrast and RFP conﬂuency were monitored and measured at intervals
by the Incucyte Zoom. Cell proliferation was reduced in RFP- cells, while RFPþ cells were able to expand and proliferate.
Images are shown for selected time points.
1079.e3 Lampis et al Gastroenterology Vol. 154, No. 4
Supplementary Figure 4. EGI-1 cells were infected with miR-21 or CTRL TRIPZ viral vector to generate inducible stable
clones. (A) miR21 expression was assessed by Taqman assays and normalized to that of RNU48. Bars represent mean and SD
of three replicates. (B) Doxycycline-activated cells were plated in 96 well plates and treated with sub-lethal concentrations of
AUY922 (5nmol/L). After 72 hrs doxycycline was removed to deactivate miR-21 expression. Cell viability was measured at
selected time points by Celigo S. Bars represent mean and SD of 12 replicates.
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Supplementary Figure 5. CRC PDOs were plated in 96-well plates and treated with AUY922 in triplicates at 20nmol/L (A) or at
scalar concentrations (B). (C) CRC PDOs were infected with a miR-21-over-expressing or control TRIPZ viral vector. (D) TRIPZ
infected CRC PDOs were treated with scalar concentrations of AUY922. miR-21 expressing cells were more resistant to
AUY922.
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